Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries

Mohamed Haseef1,2, Stephen C H Li3, Tobias Gaitt1,2

  • 1Medical School, University of Western Australia, Perth.

Insights

Hypertriglyceridemia (HTG) is a risk factor for cardiovascular disease and pancreatitis. Novel RNA-based treatments significantly lower triglycerides and reduce pancreatitis risk, with registries offering valuable real-world data.

Area of Science:

  • Cardiology
  • Endocrinology
  • Genetics

Background:

  • Hypertriglyceridemia (HTG) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis (AP).
  • Early detection and management of HTG are crucial for preventing severe complications.
  • HTG is frequently associated with other cardiometabolic risk factors like obesity, diabetes, and hepatic steatosis.

Purpose of the Study:

  • To review the etiology and novel treatments for HTG.
  • To discuss recent findings from contemporary HTG registries.
  • To highlight the importance of patient registries in understanding and managing HTG.

Main Methods:

  • Literature review of etiology and novel treatments for HTG.
  • Analysis of recent findings from HTG registries.
  • Examination of data from contemporary clinical trials and international registries.

Main Results:

  • Novel RNA-based therapies demonstrate significant triglyceride reduction and decreased AP incidence.
  • A recent trial showed benefits in patients with triglycerides >500 mg/dL, with mixed effects on lipid profiles.
  • International registries provide valuable real-world data on HTG management and outcomes.

Conclusions:

  • HTG registries offer critical insights into the link between HTG and cardiometabolic disorders.
  • Registry data can guide clinical service planning and the translation of therapeutic trial findings.
  • Harmonizing HTG definitions and improving care for severe HTG and familial chylomicronemia syndrome are necessary.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
640
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
659